Good response rates and predictors during the first year of cabergoline treatment in large invasive prolactinomas
Authors' conclusion
Approximately half of invasive prolactinoma patients achieved the composite goal within one year of cabergoline therapy. Early follow-up studies, rather than baseline characteristics, are strong predictors of treatment success.
Study context
- Population
- Patients with invasive macroprolactinomas on cabergoline followed ≥1 year; 32 males, 6 females; mean age 41.9 ± 12.8 years; baseline median prolactin 2530 (1726–5451) ng/mL; mean longest tumor diameter 36.4 ± 12.8 mm
- Participants
- 38 patients
- Exposure
- Good responders vs poor responders to cabergoline
- Good responders (GRs)n = 17
- Outcome
- Rate of good response (GR): normoprolactinemia and ≥ 50% tumor shrinkage
- Follow-up
- one-year follow-up
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Good response (GR) · first year
Patients achieving good response (GR)
17
44.7%
Observational data: associations, not effects.
Further findings
Normoprolactinemia at 3-6 months
P = 0.004
Tumor shrinkage at 3-6 months
P = 0.02
Early predictors of first-year GR · early follow-up
- Early tumor shrinkage cut-off 44.9%: sensitivity / specificity
- 88% / 62%
- Early prolactin cut-off 30 ng/mL: sensitivity / specificity
- 75% / 77%
- Baseline parameters comparable between groups
Failure to maintain goals at last visit
- Poor responders (PRs) failing normoprolactinemia
- 33.3% (p = 0.009)
- PRs failing ≥ 50% tumor shrinkage
- 42.9% (p = 0.002)
- PRs requiring surgery during follow-up
- 3
- All GRs maintained normoprolactinemia and ≥ 50% tumor shrinkage
Original publication
Good response rates and predictors during the first year of cabergoline treatment in large invasive prolactinomas. Pituitary. Published 10 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →